Skip to content

NMN and NAD+ for Fatty Liver (NAFLD/MASH): The Evidence

NR plus pterostilbene did not reduce liver fat in a 111-person trial. How NMN findings differ, and how these supplements compare with approved MASH treatments.

By Marcus HaleLongevity Research Editor
Updated

6 min read · 11 sources

On this page

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed NAFLD, can progress to inflammatory liver disease called MASH. NAD+ boosters are marketed for this condition, but animal findings and human treatment evidence need to be separated. NMN and NAD+ for kidney health raises a similar problem: evidence about a pathway does not establish protection of an organ.

The animal data behind that pitch is real and, frankly, impressive. But "impressive in mice" and "proven in people" are very different claims, and fatty liver is exactly the place where that distinction matters — because the human trials have now been done, and the results are more sobering than the supplement ads suggest. This page walks through what's genuinely established, what's only preclinical, and why NAD+ for fatty liver remains promising-but-unproven.

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD

Why the liver is a logical NAD+ target

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell that carries electrons through the reactions turning food into usable energy, and it also fuels DNA-repair enzymes and the sirtuins. Because it sits at the center of energy metabolism, low NAD+ availability can ripple outward into mitochondrial and metabolic dysfunction 1, and NAD+ tends to fall with age and metabolic stress in human tissue 2. The liver is a metabolically ferocious organ, and the leading models of fatty liver involve overwhelmed, dysfunctional mitochondria that can't keep up with a flood of dietary fat. So "restore the liver's NAD+ and you restore its mitochondria" is a clean, mechanistically sensible hypothesis.

The hypothesis

Low hepatic NAD+

High-fat diet / metabolic stress deplete liver NAD+ (rodent models)

Mitochondrial dysfunction

Impaired fat-burning → fat accumulates (steatosis)

Restore NAD+ (NMN/NR)

Reverses steatosis in MICE — but did NOT reduce liver fat in human trials

Animal mechanisms explain the research rationale. The cited human studies did not establish a significant liver-fat benefit.

The preclinical case is genuinely strong

This is the part the marketing gets right. In animal models, boosting NAD+ does remarkable things to fatty liver.

The landmark study came in 2016: in mice fed a high-fat, high-sucrose diet, nicotinamide riboside both prevented and reversed non-alcoholic fatty liver disease 3. The mechanism was elegant — the high-fat diet lowered hepatic NAD+ and crippled mitochondrial function, and restoring NAD+ triggered a SIRT1/SIRT3-dependent mitochondrial unfolded-protein response that ramped fat-burning back up 3. Subsequent work reinforced the theme, showing that engaging the NAMPT/NAD+/SIRT1 axis ameliorated NASH (the inflammatory, more dangerous form of fatty liver) in disease models 4. These models support investigating NAD+ metabolism; they do not establish a treatment for human MASH or show that every precursor has the same effects.

The clinical question is whether the benefit translates to people. (The same "strong in mice, unproven in people" gap runs through the organ next door — see NMN and NAD+ for kidney health, where the protective data is almost all in acute injury in rodents.)

The human trials: a reality check

The directly relevant NR-plus-pterostilbene trial did not meet its liver-fat endpoint. A separate small NMN study also found no significant liver-fat difference. These findings do not prove that every future formulation must fail, but they do not support selling current products as established liver treatments.

The most directly relevant trial is a 2023 study published in Hepatology: 111 adults with NAFLD were randomized to placebo or one of two doses of an NR-plus-pterostilbene supplement for six months 5. The primary endpoint — hepatic fat fraction — did not change versus placebo at either dose 5. That's the headline result, and it's the opposite of what the mouse data predicted. The supplement did move some secondary markers: at the standard dose, liver enzymes (ALT and GGT) and a toxic ceramide lipid fell significantly versus placebo, and it was generally well tolerated over the study period 5. Those secondary signals are interesting and worth following up — but a drop in a couple of inflammation markers is not the same as shrinking the fat in the liver, which is the thing the product was supposed to do and the endpoint the trial was built around.

A separate 30-person study gave overweight or obese adults aged 45 and older an NMN formulation (MIB-626) for 28 days 6. It was a short physiological study, not a dedicated MASH treatment trial. It clearly raised circulating NAD+ and produced some modest cardiometabolic shifts — small drops in body weight, LDL cholesterol, and blood pressure, which we weigh on their own terms in NAD+ for weight loss — but it showed no significant between-group change in liver or abdominal fat and no improvement in insulin sensitivity 6. Again: the biomarker moved, the liver fat didn't.

Strength of evidence

  • Preclinical → NAD+ reverses NAFLD/NASH (mice)Strong evidence

    Landmark rodent studies: prevention and reversal via SIRT-dependent mitochondrial pathways.

  • Human → NR+pterostilbene reduces liver fatNone evidence

    111-person, 6-month RCT: NO change in hepatic fat fraction vs placebo.

  • Human → NMN reduces liver / abdominal fatNone evidence

    Small 28-day physiological study; no significant liver-fat difference.

  • Human → secondary metabolic markersWeak evidence

    Inconsistent improvements in liver enzymes, lipids, or insulin sensitivity; markers, not the disease.

Interpret the trial population, intervention and endpoint separately. Liver enzymes, fat fraction and fibrosis are not interchangeable outcomes.

There is one frequently-cited human bright spot worth putting in proper context. A 2021 trial in Science found that NMN improved skeletal-muscle insulin sensitivity in prediabetic women 7 — a genuine, controlled metabolic benefit. But note what it was and wasn't: it measured muscle insulin signaling, not liver fat, and even its own authors and commenters debated how to interpret it. It's encouraging for the broader "NAD+ and metabolism" story, but it is not evidence that NMN treats fatty liver.

Why mice and humans diverge here

Why would something that reverses fatty liver in rodents fail to shrink it in people? A few honest reasons. Mouse studies use young animals with diet-induced disease, controlled genetics, and often higher relative doses for shorter, cleaner timelines — conditions that flatter an intervention. Human MASLD is heterogeneous, chronic, and tangled up with obesity, insulin resistance, diet, and genetics that no single coenzyme is likely to untangle. And the broader NAD+ literature shows this exact pattern repeatedly: a systematic review and meta-analysis of NAD+ precursors on metabolic-syndrome parameters found benefits limited and inconsistent despite reliably raised NAD+ 8, and even in other organ systems, raising the NAD+ biomarker has repeatedly failed to deliver the matching functional improvement 9. We unpack that "biomarker is not benefit" problem across the board in our pillar guide to NAD+ therapy evidence.

So should you take NMN or NR for fatty liver?

NMN and NR have not established a treatment benefit for MASLD or MASH.

  • The mechanism and preclinical data are strong 34, which is why this is an active research area and not a dead end.
  • The human trials so far have not reduced liver fat 56 ; neither trial established reversal of MASH or liver fibrosis.
  • There are encouraging secondary signals (liver enzymes, lipids, a metabolic-marker improvement here and there) 57, but secondary markers are not the disease, and a positive marker doesn't establish a clinical benefit.
  • No NAD+ booster is approved or established for NAFLD/MASH, and none should be relied on in place of the things that genuinely work.

Approved treatments are a different evidence category

MASH no longer lacks approved medicines. Rezdiffra (resmetirom) received FDA approval in 2024, and Wegovy (semaglutide) gained a MASH indication in 2025. Their indications concern adults with noncirrhotic MASH and moderate-to-advanced fibrosis, not everyone with liver fat 1011. These are accelerated approvals based on liver histology; confirmatory clinical-benefit evidence remains important.

A clinician needs to establish the diagnosis and fibrosis stage before discussing treatment eligibility. Managing weight and metabolic risk, nutrition and physical activity remains part of care. An NAD+ increase or a lower liver enzyme result does not establish the same effect as improvement in inflammation or fibrosis on the endpoints used for an approved medicine.

If you're considering an NAD+ supplement, treat it as an unproven adjunct to discuss with the clinician managing your liver, not a substitute for the proven steps. Before buying anything, understand the whole picture: start with our NAD+ therapy evidence pillar, see how the precursors differ in NMN vs NAD, check the side-effect profile, and — because high-dose niacin-family compounds and liver health intersect with cancer-pathway questions people often ask about — see our honest review of NAD+ and cancer. For product and provider comparisons, see our NAD+ rankings hub.

Frequently asked questions

Does NMN or NR reduce liver fat in fatty liver disease?

The 111-person NR-plus-pterostilbene trial did not significantly improve liver fat versus placebo. A separate small, short NMN physiological study also found no significant liver-fat difference. These findings do not establish either supplement as a treatment for MASLD or MASH.

Why is NAD+ marketed for fatty liver if the human trials are negative?

Because the preclinical (mouse) data is genuinely strong — NAD+ repletion prevents and reverses fatty liver in rodents through clear mitochondrial mechanisms. Marketing often leans on that animal data and on secondary human findings (like small drops in liver enzymes) without mentioning that the primary endpoint, liver fat, didn't change in controlled human trials.

Is there any human benefit at all from NAD+ boosters for the liver?

Some studies reported changes in liver enzymes or metabolic markers. Such changes are distinct from established reductions in liver fat, inflammation, fibrosis or liver-related complications. The NR trial also tested a combination with pterostilbene, so its results cannot be attributed to NR alone.

What actually works for fatty liver disease?

Care depends on diagnosis, fibrosis stage and metabolic risks. Rezdiffra and Wegovy have FDA indications for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis, alongside appropriate lifestyle care. These indications do not apply to everyone with fatty liver. NAD+ supplements are not substitutes for indicated treatment.

References

  1. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/
  2. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012). Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. https://pubmed.ncbi.nlm.nih.gov/22848760/
  3. Gariani K, Menzies KJ, Ryu D, et al. (2016). Eliciting the mitochondrial unfolded protein response by nicotinamide adenine dinucleotide repletion reverses fatty liver disease in mice. Hepatology. https://pubmed.ncbi.nlm.nih.gov/26404765/
  4. Yang N, Yang Q, Bao X, et al. (2023). Alternative pathway of bile acid biosynthesis contributes to ameliorate NASH after induction of NAMPT/NAD+/SIRT1 axis. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/37315437/
  5. Dellinger RW, Holmes HE, Hu-Seliger T, et al. (2023). Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. Hepatology. https://pubmed.ncbi.nlm.nih.gov/36082508/
  6. Pencina KM, Valderrabano R, Wipper B, et al. (2023). Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study. The Journal of Clinical Endocrinology & Metabolism. https://pubmed.ncbi.nlm.nih.gov/36740954/
  7. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://pubmed.ncbi.nlm.nih.gov/33888596/
  8. Oliveira-Cruz A, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
  9. Orr ME, Kotkowski E, Ramirez P, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. https://pubmed.ncbi.nlm.nih.gov/37994989/
  10. U.S. Food and Drug Administration (2024). Drug Trials Snapshots: REZDIFFRA. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezdiffra
  11. U.S. Food and Drug Administration (2025). FDA Approves Treatment for Serious Liver Disease Known as MASH. FDA. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.